Improving Family Engagement in Acute Cardiovascular Care: The NGAGE Trial
NCT ID: NCT05939427
Last Updated: 2025-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
88 participants
INTERVENTIONAL
2023-04-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will randomize 88 family members of people hospitalized in the acute cardiac ward in a 1:1 manner to either the NGAGE intervention or usual care. Family members will be eligible if the expected unit stay of their loved one is \>48 hours and if they can communicate in English or French. A family member is considered anyone with a biological, emotional, or legal relationship with the patient whom the patient wishes to be involved in their care. The primary outcome of the study will be the FAMily Engagement (FAME) score at hospital discharge. Secondary outcomes will be family mental health (by HADS score) and family care satisfaction (by FS-ICU score).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Wearable EducAtional Intervention to REduce Angina
NCT03134105
Non-contact ECG Sensor System for COVID19
NCT04341506
The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients
NCT02336919
Clinical Data Collection and Evaluation of ECG-Less Cardiac CT
NCT05949138
Effects of Remote Patient Monitoring on Heart Failure Management
NCT00778986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NGAGE tool group
Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
NGAGE tool
Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
Non-Intervention
Will receive usual care standards.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGAGE tool
Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged of at least 18 years old
* Ability to communicate in English or French
* Willing to fill out the questionnaires as per the study
Exclusion Criteria
* Inability to communicate in English or French
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lady Davis Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Goldfarb
Clinician-Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Goldfarb, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
Lady Davis Institute, McGill University, Jewish General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ladis Davis Institute
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-3590
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.